在阿尔茨海默氏症痴呆症中,宁-血管酶系统调节者的治疗影响
Daniela-Carmen Ababei1, Veronica Bild1,2, Ioana Macadan1
1Department of Pharmacodynamics and Clinical Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 16 Universitatii Street, 700115 Iasi, Romania.
Pharmaceutics
|September 28, 2023
概括
雷宁-血管酶系统 (RAS) 可能为阿尔茨海默氏症提供新的治疗方法.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 心血管研究研究心血管研究
背景情况:
- 人们越来越多地认识到氨酶系统 (RAS) 的作用超出了心血管调节的范围.
- 新出现的证据将RAS失调与神经退行性疾病联系在一起,特别是阿尔茨海默氏症痴呆症 (AD).
- 了解RAS参与阿尔茨海默氏症的发病过程对于开发新的治疗策略至关重要.
研究的目的:
- 审查RAS调节器在阿尔茨海默氏症痴呆症 (AD) 的治疗潜力.
- 为了研究血管激素转化酶抑制剂 (ACEI),血管激素受体阻断剂 (ARB) 和雷宁抑制剂在AD中的作用.
- 评估AD干预RAS调制的临床前和临床发现.
主要方法:
- 在AD中对RAS调节器的临床前研究和临床试验的文献综述.
- 分析ACEI,ARB和雷宁抑制剂影响AD病理的机制.
- 评估RAS调节的神经保护,抗炎和认知效应.
主要成果:
- 临床前数据表明,RAS调制对AD模型中的神经炎症,神经元损伤和Aβ代谢产生了有利的影响.
- ACEI降低了血管新生素II,减轻了与AD有关的神经炎症和氧化应激.
- 在AD模型中,ARBs通过阻断Ang II受体提供神经保护,改善大脑血流和认知功能.
- 列宁抑制剂向最初的RAS步骤,提供抗炎和抗氧化功效.
- 临床试验表明ARB可能比ACEI更有效地减少AD的认知衰退.
结论:
- 包括ACEI,ARB和宁抑制剂在内的RAS调节剂,为AD提供了一个有前途的治疗途径.
- 准RAS有可能减轻AD的关键病理特征,如神经炎症和Aβ积累.
- 需要进一步的临床研究,以充分阐明RAS调节器在AD治疗中的有效性和最佳使用.
关键词:
ACE 抑制剂 是 一种 ACE 抑制剂.在ARB中,ARB是ARB.在阿尔茨海默氏症痴呆症.阿利斯基伦 (aliskiren) 是一个名字.ангиотензин II 的使用宁血管氨酸 氨酸更多相关视频
08:27Establishment of a Valuable Mimic of Alzheimer's Disease in Rat Animal Model by Intracerebroventricular Injection of Composited Amyloid Beta Protein
Published on: July 29, 2018
12.0K
08:21A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
Published on: October 26, 2020
4.8K
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
454
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
454
01:25Antihypertensive Drugs: Direct Renin Inhibitors
667
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
667
01:22Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
683
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
683
01:26Alzheimer's Disease: Overview
513
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
513
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
771
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
771